Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment
British Journal of Dermatology2014Vol. 171(6), pp. 1434–1442
Citations Over TimeTop 1% of 2014 papers
Alexa B. Kimball, Gregor B. E. Jemec, Min Yang, Andrew Kageleiry, James Signorovitch, Martin M. Okun, Y. Gu, K. Wang, Parvez Mulani, M Sundaram
Abstract
In patients with HS with ≥ 3 ANs, HiSCR achievers had significant improvements in physician-rated and patient-reported HS disease severity and impact. HiSCR is a valid and meaningful endpoint for assessing HS treatment effectiveness in controlling inflammatory manifestations in this population.
Related Papers
- → Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa(2020)20 cited
- → Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience(2020)17 cited
- → Hidradenitis suppurativa in Crohn’s disease during adalimumab therapy: a paradox?(2016)16 cited
- Adalimumab treatment for hidradenitis suppurativa associated with Crohn's disease.(2014)
- → Hidradenitis suppurativa successfully treated with adalimumab(2015)